Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BBP-398 |
Synonyms | |
Therapy Description |
BBP-398 is a small molecule SHP2 inhibitor that blocks ERK signaling and potentially reduces tumor cell viability and tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P207). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BBP-398 | BBP 398|BBP398|IACS-15509|IACS 15509|IACS15509|BMS-986466|BMS986466 | SHP2 Inhibitor 20 | BBP-398 is a small molecule SHP2 inhibitor that blocks ERK signaling and potentially reduces tumor cell viability and tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P207). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04528836 | Phase I | BBP-398 | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |